₹150 per Covaxin dose to Centre not sustainable in long run: Bharat Biotech
The Hindu
“The supply price of Covaxin to the government of India at ₹150 / dose, is a non-competitive price and clearly not sustainable in the long run,” Bharat Biotech said in a statement
The supply price of Bharat Biotech’s COVID-19 vaccine Covaxin to the Central government at ₹150 per dose is not sustainable in the long run, the vaccine maker said on June 15. The Centre’s supplying price is pushing the pricing structure for the private sector upward. Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin, Bharat Biotech said justifying the higher price when compared to other COVID-19 vaccines available for the private sector in India.More Related News

Former CM B.S. Yediyurappa had challenged the first information report registered on March 14, 2024, on the alleged incident that occurred on February 2, 2024, the chargesheet filed by the Criminal Investigation Department (CID), and the February 28, 2025, order of taking cognisance of offences afresh by the trial court.